Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Tourette Syndrome | Unmet Need | US/FR/DE/UK | 2020

Login to access report north_east
Contact sales account_box

Tourette syndrome is a neurological disorder characterized by repetitive, uncontrollable movements and/or unwanted vocal sounds (tics) and typically begins in childhood. Tics range from mild to severe and can therefore significantly affect communication, daily functioning, and quality of life. Aripiprazole, pimozide, and haloperidol are the only therapies with formal approval in either the United States or Europe for Tourette syndrome, but alpha-2 agonists and dopamine-depleting agents are also used off-label. Because pharmacological treatments are usually only partially effective for controlling tics and carry unwanted side effects including somnolence, weight gain, and drug-induced movement disorders, substantial unmet need persists for more effective treatment options.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for Tourette syndrome?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What are the prevailing areas of unmet need and opportunity in Tourette syndrome?
  • What are the commercial opportunities for emerging Tourette syndrome therapies, such as Teva’s deutetrabenazine, Therapix Biosciences’ dronabinol / palmitoylethanolamide, Emalex Biosciences’ ecopipam, and Abide / Lundbeck’s ABX 1431?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new Tourette syndrome drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in January 2020

Key companies: Janssen, Lundbeck, Otsuka Pharmaceutical, Teva, Emalex Biosciences

Key drugs: Aripiprazole, clonidine, guanfacine, pimozide, risperidone, tetrabenazine, tiapride

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east